Antimicrobial Agents and Chemotherapy
AAC Recent Issues
- Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice [Experimental Therapeutics]
- Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides [Epidemiology and Surveillance]
- Editorial Board [Masthead]
- Alterations of Metabolic and Lipid Profiles in Polymyxin-Resistant Pseudomonas aeruginosa [Mechanisms of Resistance]
- Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability [Clinical Therapeutics]
- The Combination of Daptomycin and Fosfomycin Has Synergistic, Potent, and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis [Experimental Therapeutics]
- CrpP Is a Novel Ciprofloxacin-Modifying Enzyme Encoded by the Pseudomonas aeruginosa pUM505 Plasmid [Mechanisms of Resistance]
- Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model [Experimental Therapeutics]
- Report of erm(B)+ Campylobacter jejuni in the United States [Letters]
- Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata [Clinical Therapeutics]
- Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data [Clinical Therapeutics]
- Mechanistic Basis of pH-Dependent 5-Flucytosine Resistance in Aspergillus fumigatus [Mechanisms of Resistance]
- Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models [Experimental Therapeutics]
- Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose [Clinical Therapeutics]
- Comparison of Septic Shock Due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit Patients [Clinical Therapeutics]
- Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-{beta}-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model [Pharmacology]
- In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, and Its Water-Soluble Prodrug, DS11960558, against Methicillin-Resistant Staphylococcus aureus [Experimental Therapeutics]
- Clinical and Microbiological Characteristics of Candida guilliermondii and Candida fermentati [Epidemiology and Surveillance]
- A Novel Polyaminocarboxylate Compound To Treat Murine Pulmonary Aspergillosis by Interfering with Zinc Metabolism [Experimental Therapeutics]
- Molecular Characterization of OXA-198 Carbapenemase-Producing Pseudomonas aeruginosa Clinical Isolates [Mechanisms of Resistance]